Get the Stockscreener App
8.77
5.16%
0.43
After Hours:
8.61
-0.16
-1.82%
Mesoblast Ltd Adr stock is traded at $8.77, with a volume of 65,181.
It is up +5.16% in the last 24 hours and down -18.87% over the past month.
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
See More
Previous Close:
$8.34
Open:
$8.5
24h Volume:
65,181
Relative Volume:
0.43
Market Cap:
$1.00B
Revenue:
$7.50M
Net Income/Loss:
$-81.89M
P/E Ratio:
0.3137
EPS:
27.9585
Net Cash Flow:
$-63.58M
1W Performance:
-3.20%
1M Performance:
-18.87%
6M Performance:
+16.93%
1Y Performance:
+239.92%
1-Day Range:
$8.35
$8.81
1-Week Range:
$7.09
$9.10
52-Week Range:
$1.61
$11.05
Mesoblast Ltd Adr Stock (MESO) Company Profile
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
Mesoblast files annual report and meeting notice - Investing.com India
Mesoblast stock soars to 52-week high, hits $8.7 - Investing.com
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch - GlobeNewswire Inc.
Mesoblast stock gains momentum ahead of 2025 PDUFA dateJefferies - Investing.com
The Psychology of Mesoblast Ltd ADR Inc. (MESO) Price Performance: Understanding Market Sentiment - The InvestChronicle
Why Argosy Minerals, Flight Centre, Mesoblast, and Telix shares are sinking today - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 0.50% - Investing.com
Up 308% in 6 months, why is the Mesoblast share price tumbling today? - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 0.73% - Investing.com
Why Clinuvel, Mesoblast, Red Hill, and Resimac shares are sinking today - The Motley Fool
What's going on with the Mesoblast share price today? - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 1.19% By Investing.com - Investing.com
Australia shares higher at close of trade; S&P/ASX 200 up 0.34% - Investing.com India
Australia shares higher at close of trade; S&P/ASX 200 up 1.01% - Investing.com India
Mesoblast LtdADR (MESO) Price Target Increased by 5.79% to 1.56 - MSN
There is no doubt that Mesoblast Ltd ADR (MESO) ticks all the boxes. – Sete News - SETE News
Australia stocks higher at close of trade; S&P/ASX 200 up 0.81% - Investing.com
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Australia stocks lower at close of trade; S&P/ASX 200 down 0.09% By Investing.com - Investing.com
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.99% - Investing.com
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
11 Best ASX Stocks To Buy Now - Yahoo Finance
Australia stocks higher at close of trade; S&P/ASX 200 up 0.11% By Investing.com - Investing.com
Australia stocks higher at close of trade; S&P/ASX 200 up 0.39% By Investing.com - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Stock Set to Reverse Split on Friday, January 5th (NASDAQ:MESO) - MarketBeat
Top Penny Stocks for Q3 2023 - Investopedia
Here’s why Mesoblast shares are in a trading halt today - The Motley Fool Australia
Class action proposed against biotech Mesoblast after historic collapse in share price - Business News Australia
The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data - Benzinga
41 Stocks Moving in Friday's Pre-Market SessionAmarin Corp (NASDAQ:AMRN), Artelo Biosciences (NASDAQ:A - Benzinga
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rock - Benzinga
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEOi - Benzinga
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse BearishMesoblast (NASDAQ:MESO) - Benzinga
12 Biggest Mid-Day Losers For ThursdayAvalon Holdings (AMEX:AWX) - Benzinga
Exclusive Interview With Pluristem Therapeutics Inc.(NASDAQ:PSTI) President Yaky Yanay - Market Exclusive
Mesoblast (MESO) Stock Price, News & Analysis - MarketBeat
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) On Track to Becoming Largest Generics Manufacturer - The Wall Street Transcript
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology - Streetwise Reports
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):